

The case described contributes to increase the awareness of extrathoracic hypoxemia causes such as Abernethy malformation when facing a chronic hypoxemia in children and once cardiac and primary pulmonary causes have been excluded. A prompt diagnosis and proper management may prevent the development of serious complications.

Financial disclosure

The authors have no financial relationship to disclose.

Conflict of interest

The authors have no conflicts of interest to disclose.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.arbres.2021.02.005.

References

- Baiges A, Turon F, Simón-Talero M, Tasayco S, Bueno J, Zekrini K, et al. Congenital extrahepatic portosystemic shunts (abernethy malformation): an international observational study. *Hepatology*. 2020;71:658–69. <http://dx.doi.org/10.1002/hep.30817>.
- Soota K, Klair JS, LaBrecque D. Confusion for fifteen years: a case of abernethy malformation. *Clin Gastroenterol Hepatol*. 2018;16:A50. <http://dx.doi.org/10.1016/j.cgh.2018.01.003>.
- Chira RI, Calauz A, Manole S, Valean S, Micrea PA. Unusual discovery after an examination for abdominal pain: Abernethy 1b malformation and liver adenomatosis. A case report. *J Gastrointest Liver Dis*. 2017;26:85–8. <http://dx.doi.org/10.15403/jgld.2014.1121.261.abe>.
- Kinane TB, Westra SJ. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-2004. A four-year-old boy with hypoxemia. *N Engl J Med*. 2004;351:1667–75. <http://dx.doi.org/10.1056/NEJMcp049023>.
- Jain V, Sangdup T, Agarwala S, Bishoi AK, Chauhan S, Dhua A, et al. Abernethy malformation type 2: varied presentation, management and outcome. *J Pediatr Surg*. 2019;54:760–5. <http://dx.doi.org/10.1016/j.jpedsurg.2018.08.053>.
- Schaeffer DF, Laiq S, Jang HJ, John R, Adeyi OA. Abernethy malformation type II with nephrotic syndrome and other multisystemic presentation: an illustrative case for understanding pathogenesis of extrahepatic complication of congenital portosystemic shunt. *Hum Pathol*. 2013;44:432–7. <http://dx.doi.org/10.1016/j.humpath.2012.08.018>.
- Rajeswaran S, Johnston A, Green J, Riaz A, Thornburg B, Mouli S, et al. Abernethy malformations: evaluation and management of congenital portosystemic shunts. *J Vasc Interv Radiol*. 2020;31:788–94. <http://dx.doi.org/10.1016/j.jvir.2019.08.007>.
- Knirsch W, Benz DC, Bühr P, Quandt D, Weber R, Kellenberger C, et al. Catheter interventional treatment of congenital portosystemic venous shunts in childhood. *Catheter Cardiovasc Interv*. 2016;87:1281–92. <http://dx.doi.org/10.1002/ccd.26362>.
- Franchi-Abella S, Branchereau S, Lambert V, Fabre M, Steimberg C, Losay J, et al. Complications of congenital portosystemic shunts in children: therapeutic options and outcomes. *J Pediatr Gastroenterol Nutr*. 2010;51:322–30. <http://dx.doi.org/10.1097/MPG.0b013e3181d9cb92>.
- Iida T, Ogura Y, Doi H, Yagi S, Kanazawa H, Imai H, et al. Successful treatment of pulmonary hypertension secondary to congenital extrahepatic portocaval shunts (Abernethy type 2) by living donor liver transplantation after surgical shunt ligation. *Transpl Int*. 2010;23:105–9. <http://dx.doi.org/10.1111/j.1432-2277.2009.00964.x>.
- Kuo MD, Miller FJ, Lavine JE, Peterson M, Finch M. Exploiting phenotypic plasticity for the treatment of hepatopulmonary shunting in Abernethy malformation. *J Vasc Interv Radiol*. 2010;21:917–22. <http://dx.doi.org/10.1016/j.jvir.2010.01.038>.
- Rodríguez-Roisin R, Krowka MJ, Hervé PH, Fallon MB. ERS task force Pulmonary-Hepatic Vascular Disorders (PHD) scientific committee. *Eur Respir J*. 2004;24:861–80. <http://dx.doi.org/10.1183/09031936.04.00010904>.
- Noli K, Solomon M, Golding F, Charron M, Ling SC. Prevalence of hepatopulmonary syndrome in children. *Pediatrics*. 2008;121:e522–7. <http://dx.doi.org/10.1542/peds.2007-1075>.
- Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome—a liver-induced lung vascular disorder. *N Engl J Med*. 2008;358:2378–87. <http://dx.doi.org/10.1056/NEJMra0707185>.
- Light MJ, Blaisdell CJ, Homnick DN, Schechter MS, Wienberger MM. Pediatric pulmonology. Elk Grove Village: American Academy of Pediatrics; 2011.

Marc Figueras-Coll^{a,b,*}, Anna Sabaté-Rotés^b,
Ignacio Iglesias-Serrano^c, Andreu Peñas-Aguilera^d,
Mercedes Pérez-Lafuente^e

^a Pediatric Cardiology Department, Universitat de Girona, Hospital Doctor Josep Trueta, Girona, Spain

^b Pediatric Cardiology Department, Universitat Autònoma Barcelona, Hospital Vall d'Hebron, Barcelona, Spain

^c Pediatric Pneumology Department, Universitat Autònoma Barcelona, Hospital Vall d'Hebron, Barcelona, Spain

^d Pediatric Pneumology Department, Universitat de Girona, Hospital Doctor Josep Trueta, Girona, Spain

^e Interventional Radiology Department, Universitat Autònoma Barcelona, Hospital Vall d'Hebron, Barcelona, Spain

* Corresponding author.

E-mail address: mfiguerascoll@gmail.com (M. Figueras-Coll).

<https://doi.org/10.1016/j.arbres.2021.02.005>

0300-2896/ © 2021 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

COVID-19 and smoking: An opportunity to quit[☆]



Tabaco y coronavirus: una oportunidad para dejar de fumar

To the Editor:

The start of 2020 heralded high expectations for smoking cessation in Spain, due to the planned funding of 2 of the 3 first-line drugs for quitting smoking (varenicline and bupropion) by the Social Security regime. However, the arrival in March 2020 of the SARS-CoV-2 pandemic (Covid-19), with home confinement and the ensuing anxiety and stress, changed the landscape. Although logically we might think that the Covid-19 crisis would not be the ideal time to quit smoking, data are emerging that suggest the opposite.

We analyzed abstinence during confinement in patients followed in our smoking unit who had started an attempt to quit smoking between January 1, 2020, and the declaration of the state of alarm on March 13. There were 100 patients, 46% men, with a mean

age of 59 ± 9 years; 35% had high blood pressure, 8% had diabetes, and 26% had dyslipidemia. Respiratory history included chronic obstructive pulmonary disease (COPD) in 42% and obstructive sleep apnea (OSA) in 20%. All were prescribed treatment with varenicline. Smoking habits were as follows: 8 ± 2 points on the visual analogue motivational scale, 6 ± 2 points on the Fagerström test, and 16 ± 12 ppm on co-oximetry. Patients started smoking, on average, at 17 ± 5 years, and average consumption was 18 ± 8 cigarettes a day with a cumulative index of 43 ± 18 pack-years. Follow-up in our unit comprises about 6–7 visits until 1 year of abstinence is completed, the first visit taking place 2–4 weeks after quit date. With the arrival of confinement and the suspension of face-to-face visits, planned follow-up visits were made by telephone by the treating pulmonologist who resolved questions and prescribed medication electronically. Patients were asked about abstinence at 1, 3, and 6 months, including during the confinement period (March 14 to June 21, 2020). Over half (56%) of patients confirmed abstinence during confinement. If we analyze abstinence by months, we see a rate of 67% abstinence at 1 month, 52% at 3 months, and 47% at 6 months. Of those who did not stop smoking, 12% reported reducing the number of cigarettes consumed by more than half.

Previous studies have shown a 25%–35% success rate in smoking cessation in the first 6 months and up to the first year through the combination of pharmacological treatment, psychological support,

[☆] Please cite this article as: Pastor Esplá E, Castelló Faus C, Jordá Baldó A, Boira Enrique I, Chiner Vives E. Tabaco y coronavirus: una oportunidad para dejar de fumar. *Arch Bronconeumol*. 2021;57:784–785.

and specialized supervision^{1,2}. We believe that several factors contributed to the success achieved in our cases, despite confinement and its consequences.

First, smoking has been shown to be a risk factor for severe Covid-19, doubling the possibility of serious disease progression^{3–7}. Increased concern for health and a greater perception of the risk of getting ill is associated with an increased motivation to quit smoking and more successful attempts⁸. We could compare this vulnerability with hospitalization, a situation previously described as an opportunity to quit smoking⁹. All this contrasts with the fact that social distancing, confinement, and its social and economic consequences, including unemployment, increase stress and anxiety, are factors that can contribute to the increase of tobacco consumption and relapses¹⁰. A survey conducted in the U.S. among cigar smokers during the pandemic showed that, while 40% reported smoking even more in the first few days, 76% had a higher perception of the risk of Covid-19 complications. Seventy percent showed a willingness to quit in the next 6 months, and up to 46% stated that they had requested help for their attempt¹¹. Another study carried out during confinement¹² showed no differences in the percentage of smokers who increased the number of cigarettes smoked daily and the percentage that reduced their consumption. Those who reported smoking more did so because of stress or anxiety, since they really wanted to quit, but found it difficult to access medication and psychological support. Another survey in England of smokers and electronic cigarette users showed that only 1 in 10 had attempted to quit during the months of April and May 2020¹³. In the Netherlands, similar work in smokers motivated to quit showed an increase in this motivation due to the coronavirus¹⁴.

Another potential contributing factor is that confinement and exposure to secondhand tobacco smoke pose a greater risk to children and cohabitants. Confinement with children, often in small apartments without garden areas, can increase smokers' motivation to quit and protect passive smokers^{15,16}.

Second, during confinement and the state of alarm it was more difficult to buy cigarettes. Several studies have shown that difficulty in accessing tobacco products is associated with a greater likelihood of quitting¹⁷. In Spain and other European countries, small shops selling tobacco, newspapers, postage stamps, etc. were considered essential services and remained open to the public, but the bars, restaurants, gas stations and other places where cigarettes are usually sold were closed. In Spain, moreover, tobacco is also not sold via the Internet. Pulakka et al.¹⁸ showed that a distance of more than 500 m from home to the nearest tobacco outlet was associated with a 16% increase in the possibility of quitting.

Third, quitting smoking is a lifestyle change. For many quitters in the action phase, social gatherings, lunches, dinners, and drinks with friends and family are an added obstacle to quitting smoking and, in fact, are avoided by many¹⁹. Staying at home could help. Weddings, christenings, and communions, feared social gatherings for a smoker who is the process of quitting, were also suspended.

And finally, pharmacological treatment. In Spain, 3 effective smoking cessation treatments have been authorized: varenicline, nicotine replacement therapy (NRT), and bupropion²⁰. Since January 1, 2020, 2 of these 3 treatments are now funded by our social security system. Thanks to this, at the beginning of 2020, a time when many smokers decide to give up for their New Year's resolution, more smokers would have taken the decision to quit. The state of alarm was declared on Friday, March 13, 2020, when many smokers were already making a serious attempt to quit smoking.

The most important bias that might affect our results is that abstinence was declared by patients because, given the impossibility of conducting a face-to-face visit, we could not test abstinence objectively using co-oximetry.

In summary, our results indicate that, despite confinement and its consequences, a pandemic can be a good time to quit smoking, with the support of a smoking unit, telephone consultations, and drug treatment.

References

- Hartmann-Boyce J, Hong B, Livingstone-Banks J, Wheat H, Fanshawe T. Additional behavioural support as an adjunct to pharmacotherapy

- for smoking cessation. *Cochrane Database Syst Rev.* 2019;6:CD009670, <http://dx.doi.org/10.1002/14651858.CD009670.pub4>.
- Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. *JAMA.* 2014;311:193–4, <http://dx.doi.org/10.1001/jama.2013.283787>.
- Vardavas CI, Nikitara K. Covid-19 and smoking: a systematic review of the evidence. *Tob Induc Dis.* 2020;18:20, <http://dx.doi.org/10.18332/tid/119324>.
- Berlin I, Thomas D, Le Faou AL, Cornuz J. COVID-19 and Smoking. *Nicotine Tob Res.* 2020;1–3, <http://dx.doi.org/10.1093/ntr/ntaa059>, pii:ntaa059.
- Karanasos A, Aznaouridis K, Latsios G, Synetos A, Plitiria S, Tousoulis D, et al. Impact of smoking status on disease severity and mortality of hospitalized patients with covid-19 infection: a systematic review and meta-analysis. *Nicotine Tob Res.* 2020;22:1657–9, <http://dx.doi.org/10.1093/ntr/ntaa107>.
- Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. *MedRxiv preprint.* 2020, <http://dx.doi.org/10.1101/2020.04.13.20063669>.
- Jiménez-Ruiz CA, López-Padilla D, Alonso-Arroyo A, Alexandre-Benavent R, Solano-Reina S, De Granda-Orive JI. COVID-19 and smoking: a systematic review and meta-analysis of the evidence. *Arch Bronconeumol.* 2020;30:236–42, <http://dx.doi.org/10.1016/j.arbres.2020.06.024>.
- Borrelli B, Hayes RB, Dunsiger S, Fava JL. Risk perception and smoking behavior in medically ill smokers: a prospective study. *Addiction.* 2010;105:1100–8, <http://dx.doi.org/10.1111/j.1360-0443.2010.02900.x>.
- Jiménez-Ruiz CA, de Granda JA, Solano S, Riesco JA, de Higes E, Pascual JF, et al. Normativa sobre tratamiento del tabaquismo en pacientes hospitalizados. *Arch Bronconeumol.* 2017;53:387–94, <http://dx.doi.org/10.1016/j.arbres.2016.11.004>.
- Kassel JD, Stroud LR, Paronis CA. Smoking, stress, and negative affect: correlation, causation, and context across stages of smoking. *Psychol Bull.* 2003;129:270–304, <http://dx.doi.org/10.1037/0033-2909.129.2.270>.
- Kowitz S, Ross JC, Jarman KL, Kistler CE, Lazard AJ, Ranney LM, et al. Tobacco quit intentions and behaviors among cigar smokers in the united states in response to COVID-19. *Int J Environ Res Public Health.* 2020;17:5368, <http://dx.doi.org/10.3390/ijerph17155368>.
- Klemperer EM, West JC, Peasley-Miklus C, Villanti AC. Change in tobacco and electronic cigarette use and motivation to quit in response to covid-19. *Nicotine Tob Res.* 2020;22:1662–3, <http://dx.doi.org/10.1093/ntr/ntaa072>.
- Tattan-Birch H, Perski O, Jackson S, Shahab L, West R, Brown J. COVID 19, smoking, vaping and quitting: a representative population survey in England. *Addiction.* 2020, <http://dx.doi.org/10.1111/add.15251>.
- Elling JM, Crutzen R, Talhout R, deVries H. Tobacco smoking and smoking cessation in times of COVID-19. *Tob Prev Cessation.* 2020;6:39, <http://dx.doi.org/10.18332/tpc/122753>.
- Tanski SE, Wilson KM. Children and secondhand smoke: clear evidence for action. *Pediatrics.* 2012;129:170–1, <http://dx.doi.org/10.1542/peds.2011-3190>.
- Kleier JA, Mites-Campbell, Henson-Evertz K. Children's exposure to secondhand smoke, parental nicotine dependence, and motivation to quit smoking. *Pediatr Nurs.* 2017;43:35–9.
- Chaiton MO, McCreedy G, Cohen J. Tobacco retail availability and risk of relapse among smokers who make a quit attempt: a population-based cohort study. *Tob Control.* 2018;27:163–9, <http://dx.doi.org/10.1136/tobaccocontrol-2016-053490>.
- Pulakka A, Halonen JI, Kawachi I, Pentti J, Stenholm S, Jokela M, et al. Association between distance from home to tobacco outlet and smoking cessation and relapse. *JAMA Intern Med.* 2016;176:1512–9, <http://dx.doi.org/10.1001/jamainternmed.2016.4535>.
- Hitchman SC, Fong GT, Zanna MP, Thrasher JF, Laux FL. The relation between number of smoking friends, and quit intentions, attempts, and success: findings from the international tobacco control (ITC) four country survey. *Psychol Addict Behav.* 2014;28:1144–52, <http://dx.doi.org/10.1037/a0036483>.
- Anthenelli RM, Benowitz NL, West R, Aubin LS, McRae T, Lawrence D, et al. Neuro-psychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. *Lancet.* 2016;387:2507, [http://dx.doi.org/10.1016/S0140-6736\(16\)30272-0](http://dx.doi.org/10.1016/S0140-6736(16)30272-0).

Esther Pastor Esplá^{a,*}, Carmen Castelló Faus^a,
Ariana Jordá Baldó^b, Ignacio Boira Enrique^a, Eusebi Chiner Vives^a

^a Sección de Neumología, Hospital Universitario San Juan de Alicante, Alicante, Spain

^b Medicina Familiar y Comunitaria, Hospital Universitario Virgen del Puerto Plasencia, Plasencia, Cáceres, Spain

* Corresponding author.

E-mail address: epastorespla@gmail.com (E. Pastor Esplá).

<https://doi.org/10.1016/j.arbr.2021.10.009>

1579-2129/ © 2021 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.